Vaccine News at IAS 2015
Please join us! The Enterprise and partners are holding an interactive session to explore the latest in HIV vaccine design, development and testing on Sunday, 19 July at 5:00pm - 7:00pm in Room 121-122. What’s Next for HIV Vaccines: From Design to Efficacy Testing features an expert panel that will discuss and review:
- The most promising, cross-platform approaches in development for preventive and therapeutic vaccines
- Updates in efforts to build on the success of the RV144 trial
- Lessons learned from studies on novel immunogen design, unique vector platforms, mosaic antigen inserts and prime-boost vaccine regimens
- The role of emerging strategies to administer broadly neutralizing antibodies by passive immunization
- Innovative efficacy trial designs optimize the evaluation of HIV vaccine candidates
Our colleagues at IAVI have put together some additional vaccine-related conference content to watch for:
- Plenary presentations by US Ambassador Deborah Birx (Where is PEPFAR going?); Emory University’s Eric Hunter (HIV-1 Transmission); MRC-South Africa’s Glenda Gray (Vaccines), and the Human Sciences Research Council ‘s Charles Hongoro (Cost-Effectiveness of the HIV Response).
- A presentation (Progress and challenges in HIV prevention: vaccine and non-vaccine approaches) by NIAID’s Tony Fauci, 20 July, 1-2pm
- A session on new approaches to using broadly neutralizing antibodies for HIV prevention, chaired by Glenda Gray and NIAID’s John Mascola, 20 July, 11am-12:30pm.
- Satellite session: Injectable Options and Preventable Confusion, organized by AVAC, 19 July, 2:45-4:45pm.
- A report of the latest funding data from the HIV Vaccines and Microbicides Resource Tracking Working Group.